drugset / Trial / NCT02470702
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
RandomizedParallel-groupQuadruple-blindOther
Summary
This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.
Timeline
- Start
- 2015-06
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oritavancin | Other / unclassified | 1200 mg | Intravenous |
Indications
No indication recorded.